Title : A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Pub. Date : 2019 Mar

PMID : 30587441






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 INTRODUCTION: Cabozantinib is a receptor tyrosine kinases inhibitor that targets MET (c-MET), VEGF receptor 2 (VEGFR2), RET, AXL, KIT, FLT-3, and TIE-2 and previously showed promising single agent activity in recurrent ovarian cancer. cabozantinib fms related receptor tyrosine kinase 3 Homo sapiens